Adeno-associated virus-like particle (AAVLP) Head and Neck Cancer antigen (HNC) vaccine for the treatment of patients suffering from head and neck
Denmark (IMCC) - Aalborg University, Aalborg
Infectious Diseases
Health Science and Technology, Molecular Pharmacology (MP) group
John Nieland
John Nieland
English, German, Danish, Dutch
4 weeks
Cities/Months Jan Feb Mar Apr May Jun Jul Augt Sep Oct Nov Dec
Yes Yes Yes Yes Yes No No No Yes Yes Yes No
Type of Research Project
- Basic science
What is the background of the project?
In the MP group we are working on a virus like particle vaccine (AAVLP) displaying cancer mimotopes. These mimotopes are based on a clinically approved monoclonal antibody targeting a well-known and widely accepted tumor-associated antigen in head and neck cancers. The AAVLP HNC particles will, after immunization, induce a specific antibody response against the tumor-associated antigen. Therewith, the vaccine will eliminate tumor cells expressing this antigen and may also inhibit metastasis. encompassing a part of viral protein sequences which are involved in the transfer of a virus over a cellular membrane. The AAVLP Viral peptide particle will, after immunization, induce a viral peptide specific antibody response that will block the virus from entering host cells. Therewith, the vaccine will block the infection with the virus.
What is the aim of the project?
The aim of the project is the optimization of production and purification of AAVLP vaccines. AAVLP viral peptide vaccine.
What techniques and methods are used?
The steps in this project are: 1. Growing up of bacteria containing the plasmid coding for the AAVLP HNC vaccine. 2. Purify the plasmid DNA from the bacteria. 3. Transient or stable transfection of CHO cells using the PCI method. 4. Fast Protein Liquid Chromatography (FPLC) purification of the AAVLP HNC particles using an Äkta system. 5. Analyze the purified AAVLP titer using a capsid specific enzyme-linked immunosorbent assay (Elisa), and polyacrylamide gel electrophoreses (PAGE).
What is the role of the student?
What are the tasks expected to be accomplished by the student?
A plasmid has been generated in the lab where the AAVLP protein VP3 of AAV virus is mutated at site 453 and 587 to contain part of the sequence coding for the cancer mimotope. The student will grow up the bacteria containing the plasmid. After the bacteria has been grown up, the plasmid will be isolated from the bacteria. After that the plasmid has been isolated, the plasmid will be transient or stable transfected in CHO cells. After transfection the cells will be grown for 3 days in which time the AAVLP HNC particles are produced. The AAVLP HNC capsids will be purified from the CHO cells using a newly developed column material (AVB). This purification is performed by FPLC on the Äkta machine. To optimize the purification different loading and elution buffers will be tested. After purification the purity and titer of the capsids will be analyzed by ELISA and PAGE analysis.
Will there be any theoretical teaching provided (preliminary readings, lectures, courses, seminars etc)
No theoretical teaching provided.
What is expected from the student at the end of the research exchange? What will be the general outcome of the student?
- The student will prepare a presentation
What skills are required of the student? Is there any special knowledge or a certain level of studies needed?
Basic understanding of molecular biology and protein chemistry.
Are there any legal limitations in the student’s involvement
Type of students accepted
This project accepts:
- Medical students
- Graduated students (less than 6 months)
- Pre-Medical students from the American-British system
- Development of AAVLP(HPV16/31L2) Particles as Broadly Protective HPV Vaccine Candidate. Karen Nieto; Margit Weghofer; Peter Sehr; Mirko Ritter; Sebastian Sedlmeier; Balasubramanyam Karanam; Hanna Seitz; Martin Muller; Markus Kellner; Markus Horer; Uwe Michaelis; Richard B. S. Roden; Lutz Gissmann; Jurgen A. Kleinschmidt. Nieto K; Weghofer M; Sehr P; Ritter M; Sedlmeier S; et al. (2012) Development of AAVLP(HPV16/31L2) Particles as Broadly Protective HPV Vaccine Candidate. PLoS ONE 7(6): e39741. doi:10.1371/journal.pone.0039741
- Mosenson J a; Zloza A; Nieland JD; Garrett-Mayer E; Eby JM; Huelsmann EJ; et al. Mutant HSP70 reverses autoimmune depigmentation in Vitiligo. Sci Transl Med [Internet]. 2013;5(174):174ra28. Available from:
- Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17–36 epitopes. Subhashini Jagu; Balusubramanyam Karanam; Joshua W. Wang; Hatem Zayed; Margit Weghofer; Sarah A. Brendle; Karla K. Balogh; Kerstin Pino Tossi; Richard B.S. Roden; and Neil D. Christensen Vaccine. 2015 October 13; 33(42): 5553–5563. doi:10.1016/j.vaccine.2015.09.005
- Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. Josef Singer; Krisztina Manzano-Szalai; Judit Fazekas; Kathrin Thell; Anna Bentley-Lukschal; Caroline Stremnitzer; Franziska Roth-Walter; Margit Weghofer; Mirko Ritter; Kerstin Pino Tossi; Markus Hörer; Uwe Michaelis & Erika Jensen-Jarolim show less.